Literature DB >> 23587949

Key role for efflux in the preservative susceptibility and adaptive resistance of Burkholderia cepacia complex bacteria.

Laura Rushton1, Andrea Sass, Adam Baldwin, Christopher G Dowson, Denise Donoghue, Eshwar Mahenthiralingam.   

Abstract

Bacteria from the Burkholderia cepacia complex (Bcc) are encountered as industrial contaminants, and little is known about the species involved or their mechanisms of preservative resistance. Multilocus sequence typing (MLST) revealed that multiple Bcc species may cause contamination, with B. lata (n = 17) and B. cenocepacia (n = 11) dominant within the collection examined. At the strain level, 11 of the 31 industrial sequence types identified had also been recovered from either natural environments or clinical infections. Minimal inhibitory (MIC) and minimum bactericidal (MBC) preservative concentrations varied across 83 selected Bcc strains, with industrial strains demonstrating increased tolerance for dimethylol dimethyl hydantoin (DMDMH). Benzisothiazolinone (BIT), DMDMH, methylisothiazolinone (MIT), a blend of 3:1 methylisothiazolinone-chloromethylisothiazolinone (M-CMIT), methyl paraben (MP), and phenoxyethanol (PH), were all effective anti-Bcc preservatives; benzethonium chloride (BC) and sodium benzoate (SB) were least effective. Since B. lata was the dominant industrial Bcc species, the type strain, 383(T) (LMG 22485(T)), was used to study preservative tolerance. Strain 383 developed stable preservative tolerance for M-CMIT, MIT, BIT, and BC, which resulted in preservative cross-resistance and altered antibiotic susceptibility, motility, and biofilm formation. Transcriptomic analysis of the B. lata 383 M-CMIT-adapted strain demonstrated that efflux played a key role in its M-CMIT tolerance and elevated fluoroquinolone resistance. The role of efflux was corroborated using the inhibitor l-Phe-Arg-β-napthylamide, which reduced the MICs of M-CMIT and ciprofloxacin. In summary, intrinsic preservative tolerance and stable adaptive changes, such as enhanced efflux, play a role in the ability of Bcc bacteria to cause industrial contamination.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23587949      PMCID: PMC3697374          DOI: 10.1128/AAC.00140-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  43 in total

1.  Fluoroquinolone-resistant mutants of Burkholderia cepacia.

Authors:  C F Pope; S H Gillespie; J R Pratten; T D McHugh
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

2.  Outbreak of Burkholderia cepacia bacteremia caused by contaminated chlorhexidine in a hemodialysis unit.

Authors:  M P Romero-Gómez; M I Quiles-Melero; P Peña García; A Gutiérrez Altes; M A García de Miguel; C Jiménez; Sylvia Valdezate; J A Sáez Nieto
Journal:  Infect Control Hosp Epidemiol       Date:  2008-04       Impact factor: 3.254

3.  Nosocomial outbreak of two strains of Burkholderia cepacia caused by contaminated heparin.

Authors:  C-J Yang; T-C Chen; L-F Liao; L Ma; C-S Wang; P-L Lu; Y-H Chen; J-J Hwan; L-K Siu; M-S Huang
Journal:  J Hosp Infect       Date:  2008-05-29       Impact factor: 3.926

4.  Prolonged treatment of Salmonella enterica serovar Typhimurium with commercial disinfectants selects for multiple antibiotic resistance, increased efflux and reduced invasiveness.

Authors:  Kimon A G Karatzas; Mark A Webber; Frieda Jorgensen; Martin J Woodward; Laura J V Piddock; Tom J Humphrey
Journal:  J Antimicrob Chemother       Date:  2007-09-13       Impact factor: 5.790

Review 5.  Burkholderia cepacia complex bacteria: opportunistic pathogens with important natural biology.

Authors:  E Mahenthiralingam; A Baldwin; C G Dowson
Journal:  J Appl Microbiol       Date:  2008-01-24       Impact factor: 3.772

6.  Evaluation of the efficacy of disinfection procedures against Burkholderia cenocepacia biofilms.

Authors:  E Peeters; H J Nelis; T Coenye
Journal:  J Hosp Infect       Date:  2008-11-01       Impact factor: 3.926

Review 7.  Microbial diversity in pharmaceutical product recalls and environments.

Authors:  Luis Jimenez
Journal:  PDA J Pharm Sci Technol       Date:  2007 Sep-Oct

8.  Gene expression changes linked to antimicrobial resistance, oxidative stress, iron depletion and retained motility are observed when Burkholderia cenocepacia grows in cystic fibrosis sputum.

Authors:  Pavel Drevinek; Matthew T G Holden; Zhaoping Ge; Andrew M Jones; Ian Ketchell; Ryan T Gill; Eshwar Mahenthiralingam
Journal:  BMC Infect Dis       Date:  2008-09-19       Impact factor: 3.090

9.  The Burkholderia Genome Database: facilitating flexible queries and comparative analyses.

Authors:  Geoffrey L Winsor; Bhavjinder Khaira; Thea Van Rossum; Raymond Lo; Matthew D Whiteside; Fiona S L Brinkman
Journal:  Bioinformatics       Date:  2008-10-07       Impact factor: 6.937

10.  Moisturizing body milk as a reservoir of Burkholderia cepacia: outbreak of nosocomial infection in a multidisciplinary intensive care unit.

Authors:  Francisco Alvarez-Lerma; Elena Maull; Roser Terradas; Concepción Segura; Irene Planells; Pere Coll; Hernando Knobel; Antonia Vázquez
Journal:  Crit Care       Date:  2008-01-31       Impact factor: 9.097

View more
  24 in total

Review 1.  The Role of Efflux and Physiological Adaptation in Biofilm Tolerance and Resistance.

Authors:  Heleen Van Acker; Tom Coenye
Journal:  J Biol Chem       Date:  2016-04-21       Impact factor: 5.157

2.  Distribution of Burkholderia cepacia complex species isolated from industrial processes and contaminated products in Argentina.

Authors:  A López De Volder; S Teves; A Isasmendi; J L Pinheiro; L Ibarra; N Breglia; T Herrera; M Vazquez; C Hernandez; José Degrossi
Journal:  Int Microbiol       Date:  2020-11-12       Impact factor: 2.479

3.  Burkholderia cepacia complex Phage-Antibiotic Synergy (PAS): antibiotics stimulate lytic phage activity.

Authors:  Fatima Kamal; Jonathan J Dennis
Journal:  Appl Environ Microbiol       Date:  2014-12-01       Impact factor: 4.792

4.  Survival and susceptibility of Burkholderia cepacia complex in chlorhexidine gluconate and benzalkonium chloride.

Authors:  Jeong Myeong Kim; Youngbeom Ahn; John J LiPuma; David Hussong; Carl E Cerniglia
Journal:  J Ind Microbiol Biotechnol       Date:  2015-03-21       Impact factor: 3.346

Review 5.  Burkholderia cepacia Complex Bacteria: a Feared Contamination Risk in Water-Based Pharmaceutical Products.

Authors:  Mariana Tavares; Mariya Kozak; Alexandra Balola; Isabel Sá-Correia
Journal:  Clin Microbiol Rev       Date:  2020-04-15       Impact factor: 26.132

6.  Involvement of outer membrane proteins and peroxide-sensor genes in Burkholderia cepacia resistance to isothiazolone.

Authors:  Gang Zhou; Qing-shan Shi; You-sheng Ouyang; Yi-ben Chen
Journal:  World J Microbiol Biotechnol       Date:  2013-11-06       Impact factor: 3.312

7.  The contribution of antibiotic resistance mechanisms in clinical Burkholderia cepacia complex isolates: an emphasis on efflux pump activity.

Authors:  Sung-Pin Tseng; Wan-Chi Tsai; Chih-Yuan Liang; Yin-Shiou Lin; Jun-Wei Huang; Chung-Yu Chang; Yu-Chang Tyan; Po-Liang Lu
Journal:  PLoS One       Date:  2014-08-25       Impact factor: 3.240

8.  Efflux pump-mediated drug resistance in Burkholderia.

Authors:  Nicole L Podnecky; Katherine A Rhodes; Herbert P Schweizer
Journal:  Front Microbiol       Date:  2015-04-14       Impact factor: 5.640

9.  The domestication of the probiotic bacterium Lactobacillus acidophilus.

Authors:  Matthew J Bull; Keith A Jolley; James E Bray; Maarten Aerts; Peter Vandamme; Martin C J Maiden; Julian R Marchesi; Eshwar Mahenthiralingam
Journal:  Sci Rep       Date:  2014-11-26       Impact factor: 4.379

Review 10.  Potential of metabolomics to reveal Burkholderia cepacia complex pathogenesis and antibiotic resistance.

Authors:  Nusrat S Shommu; Hans J Vogel; Douglas G Storey
Journal:  Front Microbiol       Date:  2015-07-13       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.